Across TCGA pan-cancer cohorts, IFI27 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IFI27 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IFI27 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFI27 expression acts as an unfavorable survival marker.
HNSC, LUSC, and BLCA are the cancer types where IFI27 Mutation most reproducibly stratifies survival.